Brokerages Set Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Price Target at $17.25

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) has received an average recommendation of “Moderate Buy” from the five brokerages that are currently covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $17.25.

Several brokerages have weighed in on ENTA. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and set a $18.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. JMP Securities restated a “market outperform” rating and set a $21.00 target price on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, Robert W. Baird lowered their target price on shares of Enanta Pharmaceuticals from $26.00 to $20.00 and set an “outperform” rating for the company in a research note on Tuesday, November 26th.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly bought 45,000 shares of Enanta Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The stock was purchased at an average cost of $5.69 per share, with a total value of $256,050.00. Following the purchase, the chief executive officer now owns 846,638 shares in the company, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 13.89% of the stock is owned by insiders.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently modified their holdings of ENTA. JPMorgan Chase & Co. raised its position in Enanta Pharmaceuticals by 53.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 243,628 shares of the biotechnology company’s stock valued at $2,524,000 after buying an additional 85,082 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in shares of Enanta Pharmaceuticals by 34.1% in the fourth quarter. Assenagon Asset Management S.A. now owns 192,856 shares of the biotechnology company’s stock valued at $1,109,000 after purchasing an additional 49,050 shares during the last quarter. Barclays PLC lifted its position in shares of Enanta Pharmaceuticals by 294.2% in the third quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after purchasing an additional 20,478 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. acquired a new position in Enanta Pharmaceuticals during the third quarter worth $122,000. Finally, Geode Capital Management LLC grew its position in Enanta Pharmaceuticals by 3.1% in the third quarter. Geode Capital Management LLC now owns 477,351 shares of the biotechnology company’s stock valued at $4,946,000 after purchasing an additional 14,575 shares in the last quarter. 94.99% of the stock is currently owned by institutional investors.

Enanta Pharmaceuticals Price Performance

Shares of ENTA stock opened at $7.49 on Friday. Enanta Pharmaceuticals has a one year low of $4.71 and a one year high of $17.80. The stock has a market cap of $159.76 million, a P/E ratio of -1.37 and a beta of 0.54. The stock has a fifty day moving average price of $5.69 and a 200 day moving average price of $9.31.

Enanta Pharmaceuticals (NASDAQ:ENTA) last issued its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.05) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 171.57% and a negative return on equity of 73.02%. Equities research analysts anticipate that Enanta Pharmaceuticals will post -5.05 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.